Halozyme Therapeutics, Inc. (LON:0J2O)

Market Cap	8.78B +44.1%
Revenue (ttm)	1.36B +45.0%
Net Income	365.63M -18.5%
EPS	2.96 -16.2%
Shares Out	n/a
PE Ratio	26.07
Forward PE	9.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	510
Open	103.44
Previous Close	103.02
Day's Range	101.42 - 105.16
52-Week Range	59.85 - 133.94
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 423
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error